Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + bevacizumab versus osimertinib alone in EGFR-mutant T790M-positive advanced NSCLC
2016-002029-12Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib + bevacizumab with Osimertinib (2 arms). Primary endpoint: Progression-free survival. Started Feb 2017; status: completed.
02
Drugs
osimertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-002029-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002029-12.